Specific codes in ICD-10 are unique alphanumeric designations used to identify and categorize diseases, disorders, and conditions. They consist of 3-5 characters, including both letters and numbers, that provide a high level of detail and specificity.
| Language | Translation |
|---|---|
English
|
Malignant neoplasm: Accessory sinus, unspecified |
French
|
Tumeur maligne des sinus de la face, sans précision |
| Level | Code | Title | |
|---|---|---|---|
| 1 | II | Neoplasms | |
| 2 | C00-C97 | Malignant neoplasms | |
| 3 | C30-C39 | Malignant neoplasms of respiratory and intrathoracic organs | |
| 4 | C31 | Malignant neoplasm of accessory sinuses | |
| 5 | C31.9 | Malignant neoplasm: Accessory sinus, unspecified |
| Active Ingredient | Description | |
|---|---|---|
| Ifosfamide |
Ifosfamide is an antineoplastic, a cytotoxic alkylating agent. It is a prodrug and shows no in vitro cytotoxic activity until activated by microsomal enzymes. The cytotoxic activity of ifosfamide (alkylation of the nucleophilic centres in the cells) is associated with the activated oxazaphosphorine ring hydroxylated at the C4 atom which interacts with DNA-DNA cross linking. This activity manifests itself by blocking the late S and early G2 phases of the cell cycle. |
|
| Ipilimumab |
Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of reactive T-effector cells which mobilize to mount a direct T-cell immune attack against tumour cells. |
|
| Pembrolizumab |
Pembrolizumab is a humanised monoclonal antibody which binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with ligands PD-L1 and PD-L2. The PD-1 receptor is a negative regulator of T-cell activity that has been shown to be involved in the control of T-cell immune responses. |
